hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06279702, orgStudyIdInfo id: OCalisir, briefTitle: Serious Game Simulation and Comics in School Students, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-07-19, primaryCompletionDateStruct date: 2025-07-19, completionDateStruct date: 2025-07-19, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: TC Erciyes University, class: OTHER, descriptionModule briefSummary: The aim of the study is to determine the effect of first aid training for injuries given to secondary school students through serious game simulation and comic books on knowledge, skills and motivation.Hypotheses:H1: First aid training given through simulation applications affects the level of knowledge.H2: First aid training given through simulation applications affects the skill level.H3: First aid training given with simulation application affects motivation.H4: First aid training given with comics affects the level of knowledge.H5: First aid training given with comic books affects the skill level.H6: First aid training given with comics affects motivation.METHOD: The research will be conducted as a randomized controlled experimental study with a pre-test-post-test design with children studying in the 5th and 6th grades of schools in the central district of Aksaray. One group will be given first aid training for injuries prepared with serious games, the other group will be given first aid training for injuries prepared with comic books. No intervention will be made to the control group. Serious game scenario software prepared based on the literature will be integrated into the computer. Appropriate statistics will be made after the research by applying the prepared data collection tools. With this research, the gap in the literature will be filled, children's first aid knowledge and skills in injuries will be increased, and school health nurses will be provided with up-to-date teaching material., conditionsModule conditions: First Aid, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: serious game and comics, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 54, type: ACTUAL, armsInterventionsModule interventions name: SERIOUS GAME, interventions name: COMICS, outcomesModule primaryOutcomes measure: Motivation Scale for Teaching Materials, primaryOutcomes measure: Student Knowledge Level Evaluation Form for First Aid Application in Injuries, primaryOutcomes measure: Student Skill Level Evaluation Form for First Aid Application in Injuries, eligibilityModule sex: ALL, minimumAge: 9 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Özlem Çalışır, city: Aksaray, state: Center, zip: 68200, country: Turkey, geoPoint lat: 38.37255, lon: 34.02537, hasResults: False
protocolSection identificationModule nctId: NCT06279689, orgStudyIdInfo id: CJTCDZ2301, briefTitle: Echography Study_Anthropometric Measurements, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Crossject, class: INDUSTRY, descriptionModule briefSummary: This is a multi-center, exploratory, estimation study in both adult and pediatric populations. There is no investigational product injection during this study The exploratory objective of this study is to evaluate the anatomical characteristics of both anterolateral thighs in healthy adult and healthy pediatric populations (2 to 17 years old) by ultrasound scan before and while applying a force similar to the ZENEO® triggering force.In the healthy adult population, anatomical characteristics of one shoulder (deltoid) and one upper arm (biceps and triceps) will also be evaluated by ultrasound scan before and while applying a force similar to ZENEO® triggering force.Only ultrasound procedures will be performed using an investigational ultrasound system. All subjects will be asked to undergo 1 on site visit (Study Visit) during which the eligibility assessment and the ultrasound scans will be performed., conditionsModule conditions: Healthy Subjects, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound scans, outcomesModule primaryOutcomes measure: STBD : Skin To Bone Distance, primaryOutcomes measure: STMD: Skin To Muscle Distance, primaryOutcomes measure: Thickness of skin layers (dermis, hypodermis), primaryOutcomes measure: Thickness of muscle layers, secondaryOutcomes measure: Circumferences measurements (thigh, upper arm, waist, hip), eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 70 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06279676, orgStudyIdInfo id: SaFeGreff, briefTitle: Improvement of Women's Health After Allogeneic Stem Cell Transplantation, acronym: SaFeGreff, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2028-07, completionDateStruct date: 2028-12, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Ciusss de L'Est de l'Île de Montréal, class: OTHER, collaborators name: Centre hospitalier de l'Université de Montréal (CHUM), descriptionModule briefSummary: The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women., conditionsModule conditions: GVHD, Chronic, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Define the incidence and describe clinical presentation of vulvovaginal cGVHD after allogeneic stem cell transplants reflecting modern transplant practice., secondaryOutcomes measure: Evaluate genital cGVHD treatment response, secondaryOutcomes measure: Evaluate the frequency of premature ovarian failure, secondaryOutcomes measure: Measure the incidence and prevalence of HPV infection, secondaryOutcomes measure: Evaluate the quality of life (QoL) of allografted women, secondaryOutcomes measure: Evaluate intimacy within relationships of allografted women, secondaryOutcomes measure: Evaluate sexual function of allografted women, secondaryOutcomes measure: Evaluate sexual distress of allografted women, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06279637, orgStudyIdInfo id: PRO00046457, briefTitle: Joint Patient and Caregiver Intervention for Older African Americans With Type 2 Diabetes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2026-07, completionDateStruct date: 2026-07, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Medical College of Wisconsin, class: OTHER, descriptionModule briefSummary: This study will test the preliminary efficacy of a joint patient/informal caregiver telephone-delivered intervention that includes diabetes education; problem solving around social needs; and behavioral activation for older African Americans with poorly controlled type 2 diabetes by randomizing 100 patient/caregiver dyads to the Joint Home intervention (n=50) and usual care (n=50) arms.The aims of the study are:Aim 1: To test the preliminary efficacy of home-based, joint patient and caregiver intervention (Joint Home-DM-BAT) on patient clinical outcomes (hemoglobin A1c, blood pressure, and LDL-Cholesterol).Aim 2: To test the preliminary efficacy of home-based, joint patient and caregiver intervention (Joint Home-DM-BAT) Joint Home DM-BAT on patient quality of life.Aim 3: To test the preliminary efficacy of home-based, joint patient and caregiver intervention (Joint Home-DM-BAT) on caregiver quality of life and caregiver burden., conditionsModule conditions: Type 2 Diabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Joint Home-DM-BAT Intervention, interventions name: Usual Care, outcomesModule primaryOutcomes measure: Glycemic Control (Hemoglobin A1C [HbA1C]), eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06279624, orgStudyIdInfo id: NRCT9-4, briefTitle: Effectiveness of the PCV13 in Older Thai Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Mahidol University, class: OTHER, collaborators name: National Research Council of Thailand, descriptionModule briefSummary: This is the matched 1:2 case-control study, prospectively collect case and control who are diagnosed with pneumococcal or non-pneumococcal community acquired pneumonia (CAP), accordingly from November 2023 through October 2024. The investigators define a CASE as a person aged ≥60 years due to pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge. While a CONTROL is defined as a person aged ≥60 years due to non-pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge.The goal of this observational study is to evaluate the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) in pneumococcal CAP in Thai adults aged ≥ 60 years with or without any medical conditions.The main questions it aims to answer is:• What are the effectiveness of PCV13 for preventing all typed, vaccine typed, or non-vaccine typed of pneumococcal CAP among Thai older adults?The investigators retrospectively collect cases and control who are diagnosed with CAP accordingly from January 2012 through October 2023. The investigators define case and control the same as prospective method, but all data were retrieved from archive database.-The investigators select a 1:2 matched control with criteria as follows; 10-year-interval of age, ward (the same patient care such as out or in-patient, or admitted in the same level ward).Participants will be* collated from hospital database regarding their CAP illnesses by pneumococcal and non-pneumococcal pneumonia condition.* explored their vaccine status by either vaccine book checking or hospital database.Researcher will compare the effectiveness of PCV13 to prevent all typed, vaccine typed and non-vaccine typed pneumococcal pneumonia., conditionsModule conditions: Community-acquired Pneumonia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: OTHER, enrollmentInfo count: 840, type: ESTIMATED, outcomesModule primaryOutcomes measure: Vaccine effectiveness of PCV13 on all types of pneumococcal CAP, secondaryOutcomes measure: Vaccine effectiveness of PCV13 on PCV13 (vaccine typed) and non-PCV13 (non-vaccine typed) pneumococcal CAP, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06279611, orgStudyIdInfo id: LY007C1101, briefTitle: An Evaluation of LY007 Cell Injection for r/r B-NHL, acronym: r/r B-NHL, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-12-25, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2026-05-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Shanghai Longyao Biotechnology Inc., Ltd., class: OTHER, collaborators name: The First Affiliated Hospital with Nanjing Medical University, collaborators name: Ruijin Hospital, descriptionModule briefSummary: An evaluation of LY007 cell injection for recurrent/refractory CD20 was positive Tolerability, safety, and efficacy of B-cell non-Hodgkin lymphoma in open, single-arm Phsea I Clinical research, conditionsModule conditions: B-NHL, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: LY007, outcomesModule primaryOutcomes measure: Maximum tolerated dose or clinically recommended dose, primaryOutcomes measure: Dose limiting toxicity, primaryOutcomes measure: Adverse Events, Serious Adverse Events, Adverse Events of Particular Concern, secondaryOutcomes measure: PK aspect, secondaryOutcomes measure: PK aspect, secondaryOutcomes measure: PD aspect, secondaryOutcomes measure: therapeutic effect, secondaryOutcomes measure: Anti LY007 antibody, secondaryOutcomes measure: The titer of human anti mouse antibody, otherOutcomes measure: Exploratory study endpoint, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ruijin hospital, status: RECRUITING, city: Shanghai, state: Shanghai, country: China, contacts name: zhao weili, MD, role: CONTACT, phone: 13512112076, phoneExt: 610707, email: zwl_trial@163.com, contacts name: yan zixun, MD, role: CONTACT, phone: +8613482056727, phoneExt: 610707, email: yanzixun125@163.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06279572, orgStudyIdInfo id: 20-011624, secondaryIdInfos id: NCI-2022-09618, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 20-011624, type: OTHER, domain: Mayo Clinic Institutional Review Board, briefTitle: Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-04-22, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches., conditionsModule conditions: Acute Myeloid Leukemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Biospecimen Collection, interventions name: Bone Marrow Aspirate, interventions name: Electronic Health Record Review, outcomesModule primaryOutcomes measure: Immune profile of treatment naive acute myeloid leukemia (AML) patients receiving azacitidine plus venetoclax chemotherapy, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Arizona, status: NOT_YET_RECRUITING, city: Scottsdale, state: Arizona, zip: 85259, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Cecilia Y. Arana Yi, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.50921, lon: -111.89903, locations facility: Mayo Clinic in Florida, status: RECRUITING, city: Jacksonville, state: Florida, zip: 32224-9980, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Talha Badar, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.33218, lon: -81.65565, locations facility: Mayo Clinic in Rochester, status: NOT_YET_RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Mithun V. Shah, M.D., Ph.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06279546, orgStudyIdInfo id: IECED-12345, briefTitle: Artificial Intelligence vs Endoscopist Identification in EUS Normal Anatomy, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2023-10-01, completionDateStruct date: 2024-01-26, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Instituto Ecuatoriano de Enfermedades Digestivas, class: OTHER, collaborators name: The Methodist Hospital Research Institute, collaborators name: Baylor Saint Luke's Medical Center, collaborators name: Beth Israel Deaconess Medical Center, collaborators name: Barra Life Medical Center, Brazil, collaborators name: Hospital Clinico Universitario de Santiago, collaborators name: Universitair Ziekenhuis Brussel, collaborators name: Hospital Civil de Morelia, Michoacan, collaborators name: ELIAS Emergency University Hospital, collaborators name: Larkin Community Hospital, collaborators name: Carol Davila University of Medicine and Pharmacy, collaborators name: mdconsgroup, Guayaquil, Ecuador, descriptionModule briefSummary: Endoscopic ultrasound (EUS) visual impression is operator-dependant and can hinder diagnostic accuracy, especially in less experienced endoscopists. The implementation of artificial intelligence can potentially mitigate operator dependency and interpretation variability, helping or improving the overall accuracy.The investigators therefore aim to compare diagnostic accuracy between artificial intelligence (AI)-based model and the endoscopists when identifying normal anatomical structures in EUS-procedures., conditionsModule conditions: Gastrointestinal Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Detection of structures, outcomesModule primaryOutcomes measure: Diagnostic accuracy, secondaryOutcomes measure: Interobserver agreement, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IECED, city: Guayaquil, state: Guayas, zip: 090505, country: Ecuador, geoPoint lat: -2.20584, lon: -79.90795, hasResults: False
protocolSection identificationModule nctId: NCT06279533, orgStudyIdInfo id: LV232-02, briefTitle: Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-27, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Vigonvita Life Sciences, class: INDUSTRY, descriptionModule briefSummary: This study is divided into two parts: the safety, tolerability, pharmacokinetic profiles of LV232 capsules after multiple ascending doses (hereinafter referred to as "PK characteristics of multiple ascending doses study ") and food effect study (hereinafter referred to as "FE study"). A total of 48 subjects are planned to be enrolled. The two parts of the study can be carried out simultaneously, and there is no order requirement., conditionsModule conditions: Healthy Subjects, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: PK characteristics of multiple ascending doses study is parallel design, and FE study is crossover design, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: PK characteristics of multiple ascending doses study is double-blinded, placebo-controlled design, and FE study is open-label design, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: LV232/Placebo, interventions name: LV232, outcomesModule primaryOutcomes measure: Tmax, primaryOutcomes measure: Cmax, primaryOutcomes measure: T1/2, primaryOutcomes measure: AUC0-t, primaryOutcomes measure: AUC0-24h, primaryOutcomes measure: AUC0-∞, secondaryOutcomes measure: Number of participants with treatment emergent treatment-related adverse event(s), secondaryOutcomes measure: Laboratory test, secondaryOutcomes measure: Vital signs, secondaryOutcomes measure: Number of participants with ECG findings of potential clinical importance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Shanghai Xuhui Central Hospital, status: RECRUITING, city: Shanghai, country: China, contacts name: Chen Yu, role: CONTACT, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False